We are live on ! Find out more
KRYS icon

Krystal Biotech
KRYS

264 hedge funds and large institutions have $4.35B invested in Krystal Biotech in 2024 Q4 according to their latest regulatory filings, with 37 funds opening new positions, 95 increasing their positions, 97 reducing their positions, and 52 closing their positions.

New
Increased
Maintained
Reduced
Closed

72% more call options, than puts

Call options by funds: $63.3M | Put options by funds: $36.8M

0% more funds holding in top 10

Funds holding in top 10: 6 → 6 (0)

2% less repeat investments, than reductions

Existing positions increased: 95 | Existing positions reduced: 97

1.87% less ownership

Funds ownership: 98.44% → 96.57% (-1.9%)

7% less funds holding

Funds holding: 283 → 264 (-19)

15% less capital invested

Capital invested by funds: $5.15B → $4.35B (-$796M)

29% less first-time investments, than exits

New positions opened: 37 | Existing positions closed: 52

Holders
264
Holders Change
-19
Holders Change %
-6.71%
% of All Funds
3.48%
Holding in Top 10
6
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.08%
New
37
Increased
95
Reduced
97
Closed
52
Calls
$63.3M
Puts
$36.8M
Net Calls
+$26.5M
Net Calls Change
+$3.95M

Top Buyers

Rank Fund Capital Flow
1
SCM
Soleus Capital Management
Connecticut
+$25.1M
2
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$12.6M
3
Citigroup
Citigroup
New York
+$11.5M
4
UBS Group
UBS Group
Switzerland
+$11.3M
5
IHAM
Integral Health Asset Management
New York
+$9.76M

Top Sellers

Rank Fund Capital Flow
1
FLSM
Frazier Life Sciences Management
California
-$35.5M
2
State Street
State Street
Massachusetts
-$30.8M
3
Jennison Associates
Jennison Associates
New York
-$18.9M
4
Invesco
Invesco
Georgia
-$16M
5
Allspring Global Investments
Allspring Global Investments
North Carolina
-$14.5M
Name Holding Trade Value Shares
Change 		Change in
Stake
MYIA
301
Mount Yale Investment Advisors
Colorado
– -$187K -1,027 Closed
DB
302
Danske Bank
Denmark
– -$54.6K -300 Closed
VFA
303
Values First Advisors
Tennessee
– -$53.1K -292 Closed
LP
304
LMR Partners
United Kingdom
– -$41.2K -232 Closed
JPWM
305
Jamison Private Wealth Management
Georgia
– -$27.3K -150 Closed
CAS
306
Coppell Advisory Solutions
Texas
– -$18.8K -106 Closed
ACM
307
ADAR1 Capital Management
Texas
– -$18.2K -100 Closed
Walleye Capital
308
Walleye Capital
New York
– -$17.2K -97 Closed
MIM
309
Macroview Investment Management
Maryland
– -$8.56K -47 Closed
LOIM
310
Liberty One Investment Management
Illinois
– -$2.37K -13 Closed
AGWCA
311
Annis Gardner Whiting Capital Advisors
Florida
– -$1.82K -10 Closed
AAP
312
Arax Advisory Partners
Colorado
– -$1.09K -6 Closed
CPA
313
Capital Performance Advisors
California
– -$728 -4 Closed
BF
314
BOK Financial
Oklahoma
– -$352 -2 Closed
MFG
315
Mendota Financial Group
Wisconsin
– -$365 -2 Closed
9 10 11 12
13

KRYS Hedge Fund Activity: Q4 2024 in Review

264 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Krystal Biotech (KRYS) for Q4 2024, worth a combined $4.35B — down 15% from $5.15B a quarter earlier.

Sellers outnumbered buyers: 52 funds closed out of KRYS and 37 opened new positions — a net loss of 15 holders — while 97 trimmed existing stakes and 95 added.

The largest buyer was Soleus Capital Management, adding an estimated $25.1M. The largest seller was Frazier Life Sciences Management, cutting an estimated $35.5M.

  • 264 institutional investors held Krystal Biotech (KRYS) as of Q4 2024, down from 283 in Q3 2024.
  • Funds reported $4.35B of Krystal Biotech stock for Q4 2024, down 15% quarter-over-quarter.
  • 37 funds opened new Krystal Biotech positions in Q4 2024 and 52 closed out, a net change of -15 holders.
  • The largest Krystal Biotech buyer in Q4 2024 was Soleus Capital Management, an estimated $25.1M added.
  • The largest Krystal Biotech seller in Q4 2024 was Frazier Life Sciences Management, an estimated $35.5M sold.

Based on aggregated 13F filings for Q4 2024.